Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorDivision of Gastroenterology of the Medicine Course at Federal University of Piauí-
Autor(es): dc.contributorUniversity of Vale do Itajaí-
Autor(es): dc.contributorFederal University of Juiz de Fora-
Autor(es): dc.contributorUniversidade Federal de São Carlos (UFSCar)-
Autor(es): dc.contributorUniversidade Estadual de Campinas (UNICAMP)-
Autor(es): dc.contributorFederal University of Paraíba-
Autor(es): dc.contributorGastroenterology-
Autor(es): dc.contributorPontificia Universidade Católica do Paraná (PUCPR)-
Autor(es): dc.contributorUniversidade do Oeste de Santa Catarina (UNOESC)-
Autor(es): dc.contributorUniversidade Federal do Paraná (UFPR)-
Autor(es): dc.contributorSete – Specialized Medical Center-
Autor(es): dc.contributorHospital Universitário da Universidade Federal do Piauí-
Autor(es): dc.creatorda Costa Ferreira, Sandro-
Autor(es): dc.creatorParra, Rogério Serafim-
Autor(es): dc.creatorSassaki, Ligia Yukie-
Autor(es): dc.creatorParente, José Miguel Luz-
Autor(es): dc.creatorde Mello, Munique Kurtz-
Autor(es): dc.creatorChebli, Liliana Andrade-
Autor(es): dc.creatorLuporini, Rafael Luís-
Autor(es): dc.creatorAlves Junior, Antonio José Tiburcio-
Autor(es): dc.creatorFirmino Nóbrega, Fernando Jorge-
Autor(es): dc.creatorda Silva, Bruno César-
Autor(es): dc.creatorMiranda, Eron Fábio-
Autor(es): dc.creatorQuaresma, Abel Botelho-
Autor(es): dc.creatorNicollelli, Guilherme Mattioli-
Autor(es): dc.creatorGasparini, Rodrigo Galhardi-
Autor(es): dc.creatorDutra, Renata de Medeiros-
Autor(es): dc.creatorVasconcelos, Juarez Roberto de Oliveira-
Autor(es): dc.creatorda Silva, Katia da Conceição-
Autor(es): dc.creatorMagro, Daniéla Oliveira-
Autor(es): dc.creatorImbrizi, Marcello Rabello-
Autor(es): dc.creatorNagasako, Cristiane Kibune-
Autor(es): dc.creatorFéres, Omar-
Autor(es): dc.creatorTroncon, Luiz Ernesto de Almeida-
Autor(es): dc.creatorKotze, Paulo Gustavo-
Autor(es): dc.creatorChebli, Júlio Maria Fonseca-
Data de aceite: dc.date.accessioned2025-08-21T21:10:00Z-
Data de disponibilização: dc.date.available2025-08-21T21:10:00Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2024-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1016/j.gastrohep.2025.502396-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/301334-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/301334-
Descrição: dc.descriptionObjective: Vedolizumab (VDZ) and infliximab (IFX) are first-line therapies for moderate-to-severe ulcerative colitis (UC). Despite their widespread use, there are no direct comparative studies, and real-world data, particularly in Latin America, are limited. This study compared the effectiveness and safety of VDZ and IFX in biologic-naïve UC patients. Methods: This retrospective cohort study included patients with moderate-to-severe UC (Mayo score 6–12, endoscopic sub-score ≥2) treated with VDZ or IFX. Primary endpoints were clinical remission (partial Mayo score ≤2), endoscopic remission (Mayo sub-score = 0), and steroid-free clinical remission at week 52. Secondary endpoints included clinical response, endoscopic response, biological therapy optimization, adverse events (AEs), hospitalizations, and biochemical remission at week 52. Propensity score adjustment (1/PS) was used to adjust for potential confounders. Results: A total of 297 UC patients (156 IFX, 141 VDZ) were analyzed. Clinical remission at week 52 was 82.3% for VDZ and 77.6% for IFX (p = 0.11), while endoscopic remission was higher in VDZ patients (47.4% vs. 33.1%, p = 0.03). Steroid-free clinical remission rates were similar between groups (p = 0.98). Endoscopic response at week 52 favored VDZ (78.4% vs. 62.7%, p < 0.001), and VDZ had higher treatment persistence (80.8% vs. 61.8%, p < 0.001). AEs and hospitalizations were more frequent in IFX patients (p < 0.001). Conclusions: Both VDZ and IFX are effective in biologic-naïve UC patients, however VDZ demonstrated superior endoscopic outcomes, higher treatment persistence, and a better safety profile, supporting its use as a first-line therapy.-
Descrição: dc.descriptionDepartment of Medicine Ribeirão Preto Medical School University of São Paulo, Ribeirão Preto-
Descrição: dc.descriptionDepartment of Surgery and Anatomy Ribeirão Preto Medical School University of São Paulo, SP-
Descrição: dc.descriptionDepartment of Internal Medicine Medical School Sao Paulo State University (UNESP), Campus Botucatu-
Descrição: dc.descriptionHealth Science Center Division of Gastroenterology of the Medicine Course at Federal University of Piauí, Teresina-
Descrição: dc.descriptionUniversity of Vale do Itajaí, Santa Catarina-
Descrição: dc.descriptionDivision of Gastroenterology Department of Medicine Inflammatory Bowel Disease Center Federal University of Juiz de Fora-
Descrição: dc.descriptionDepartment of Medicine Federal University of São Carlos (UFSCar), São Carlos-
Descrição: dc.descriptionDepartment of Surgery PUC-Campinas Medical School PUC-Campinas University, Campinas-
Descrição: dc.descriptionDepartment of Gastroenterology Lauro Wanderley Hospital Federal University of Paraíba, João Pessoa-
Descrição: dc.descriptionHospital da Bahia Gastroenterology, Salvador-
Descrição: dc.descriptionPontificia Universidade Católica do Paraná (PUCPR)-
Descrição: dc.descriptionUniversidade do Oeste de Santa Catarina (UNOESC)-
Descrição: dc.descriptionHospital de Clínicas da UFPR-
Descrição: dc.descriptionSete – Specialized Medical Center-
Descrição: dc.descriptionDepartment of Internal Medicine São Paulo State University (Unesp) Medical School-
Descrição: dc.descriptionHospital Universitário da Universidade Federal do Piauí-
Descrição: dc.descriptionDepartment of Surgery State University of Campinas UNICAMP, SP-
Descrição: dc.descriptionDepartment of Surgery Faculty of Medicine University of Campinas, Campinas-
Descrição: dc.descriptionDepartment of Medicine State University of Campinas UNICAMP, SP-
Descrição: dc.descriptionHealth Sciences Postgraduate Program Pontificia Universidade Católica do Paraná (PUCPR)-
Descrição: dc.descriptionDepartment of Internal Medicine Medical School Sao Paulo State University (UNESP), Campus Botucatu-
Descrição: dc.descriptionDepartment of Internal Medicine São Paulo State University (Unesp) Medical School-
Idioma: dc.languageen-
Idioma: dc.languagees-
Relação: dc.relationGastroenterologia y Hepatologia-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectInflammatory bowel disease-
Palavras-chave: dc.subjectInfliximab-
Palavras-chave: dc.subjectUlcerative colitis-
Palavras-chave: dc.subjectVedolizumab-
Título: dc.titleClinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study-
Título: dc.titleEficacia clínica y seguridad de vedolizumab frente a infliximab en pacientes con colitis ulcerosa sin tratamiento biológico: un estudio observacional multicéntrico comparativo en el mundo real-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.